ebook: Accelerating antibody discovery
Hybridoma-based antibody discovery: the challenges and how to overcome them using microfluidic picodroplet technology.
List view / Grid view
Hybridoma-based antibody discovery: the challenges and how to overcome them using microfluidic picodroplet technology.
In vitro evaluation of hepatic function using a primary human hepatocyte 3D spheroid culture system
Hypoxia measurements in live and fixed cells using fluorescence microscopy and high-content imaging
A new technology developed by scientists combines small molecule screening methods with machine learning algorithms to identify novel antibiotics that inhibit ribosomes.
A new technique has been developed which has the potential to harness bacteria to produce billions of different drug candidates to treat diseases like cancer.
There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
A library of products derived from more than 10,000 fungi has been established which could lead to the discovery of new drugs.
Research has found that artificial intelligence in drug discovery will be worth $1,434 million by the end of 2024.
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
Find out how to accelerate and improve selective single cell cloning with advanced microfluidic dispensing.
A machine-learning algorithm has been created that automates high-throughput screens of epigenetic medicines.
A drug discovery platform for mental health treatment could also help to identify mechanisms for the treatment of substance use disorders.
Automated fluorescence imaging and quantification of cell viability, with EVOS cell imaging system
A new process for identifying and biosynthesising drug candidates has been discovered by researchers at the Carl R Woese Institute for Genomic Biology.